1.09
price up icon0.93%   0.01
after-market Dopo l'orario di chiusura: 1.07 -0.02 -1.83%
loading
Precedente Chiudi:
$1.08
Aprire:
$1.09
Volume 24 ore:
114.64K
Relative Volume:
0.20
Capitalizzazione di mercato:
$32.53M
Reddito:
-
Utile/perdita netta:
$-64.73M
Rapporto P/E:
-0.3893
EPS:
-2.8
Flusso di cassa netto:
$-53.29M
1 W Prestazione:
-1.80%
1M Prestazione:
+1.87%
6M Prestazione:
-57.42%
1 anno Prestazione:
-92.76%
Intervallo 1D:
Value
$1.08
$1.10
Intervallo di 1 settimana:
Value
$1.07
$1.12
Portata 52W:
Value
$0.87
$22.22

An 2 Therapeutics Inc Stock (ANTX) Company Profile

Name
Nome
An 2 Therapeutics Inc
Name
Telefono
(650) 331-9090
Name
Indirizzo
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Name
Dipendente
36
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
ANTX's Discussions on Twitter

An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-07-18 Ripresa Oppenheimer Outperform

An 2 Therapeutics Inc Borsa (ANTX) Ultime notizie

pulisher
Oct 31, 2024

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - BioSpace

Oct 31, 2024
pulisher
Oct 29, 2024

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Yahoo Finance

Oct 29, 2024
pulisher
Oct 24, 2024

Intellia Presents Positive Results from the Phase 2 Study - GlobeNewswire

Oct 24, 2024
pulisher
Oct 24, 2024

Viking Therapeutics Inc (VKTX) Q3 2024 Earnings Call Highlights: Strong Financial Position Amid ... - Yahoo Finance

Oct 24, 2024
pulisher
Oct 15, 2024

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire

Oct 15, 2024
pulisher
Oct 09, 2024

Summit Therapeutics Inc (SMMT) Q2 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire

Oct 09, 2024
pulisher
Oct 08, 2024

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease - Business Wire

Oct 08, 2024
pulisher
Oct 07, 2024

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. - GlobeNewswire

Oct 07, 2024
pulisher
Oct 07, 2024

Intellia Therapeutics Announces Initiation of HAELO Phase 3 - GlobeNewswire

Oct 07, 2024
pulisher
Oct 02, 2024

Around the Helix: Cell and Gene Therapy Company Updates – October 2, 2024 - CGTLive™

Oct 02, 2024
pulisher
Sep 24, 2024

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 - Yahoo Finance

Sep 24, 2024
pulisher
Sep 24, 2024

Araris Doubles Down With Dual-payload ADC - BioProcess Online

Sep 24, 2024
pulisher
Sep 23, 2024

Black Diamond Therapeutics Announces Initial Phase 2 Data - GlobeNewswire

Sep 23, 2024
pulisher
Sep 23, 2024

Ildikó Enyedi working on her new feature, Silent Friend - Cineuropa

Sep 23, 2024
pulisher
Sep 23, 2024

Boss Brown calls on Ayr players to step up after losing top scorer for season - Ayr Advertiser

Sep 23, 2024
pulisher
Sep 22, 2024

Black Diamond Therapeutics to Host Webcast Presentation of - GlobeNewswire

Sep 22, 2024
pulisher
Sep 22, 2024

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - Yahoo Finance

Sep 22, 2024
pulisher
Sep 22, 2024

Scott Brown admits Anton Dowds injury is huge blow for Ayr United as he challenges others to step up - Daily Record

Sep 22, 2024
pulisher
Sep 21, 2024

Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa

Sep 21, 2024
pulisher
Sep 20, 2024

Adicet Bio reports promising ADI-001 therapy data - Investing.com

Sep 20, 2024
pulisher
Sep 19, 2024

Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM

Sep 19, 2024
pulisher
Sep 19, 2024

Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting - BioSpace

Sep 19, 2024
pulisher
Sep 19, 2024

Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha

Sep 19, 2024
pulisher
Sep 19, 2024

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire

Sep 19, 2024
pulisher
Sep 18, 2024

Agatha All Along Episode 2 Cast & Characters Guide (Photos) - The Direct

Sep 18, 2024
pulisher
Sep 18, 2024

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire

Sep 18, 2024
pulisher
Sep 18, 2024

iView Therapeutics completes enrollment in phase 1/2 trial for ophthalmic eyelid wipe for the treatment of dry eye disease - Ophthalmology Times

Sep 18, 2024
pulisher
Sep 17, 2024

VERV CLASS ACTION: Verve Therapeutics, Inc. Stockholders - GlobeNewswire

Sep 17, 2024
pulisher
Sep 17, 2024

IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients - PR Newswire

Sep 17, 2024
pulisher
Sep 17, 2024

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern - Yahoo Finance

Sep 17, 2024
pulisher
Sep 16, 2024

Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 - Yahoo Finance

Sep 16, 2024
pulisher
Sep 14, 2024

Acrivon Therapeutics Reports Positive Endometrial Cancer - GlobeNewswire

Sep 14, 2024
pulisher
Sep 12, 2024

Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration - PR Newswire

Sep 12, 2024
pulisher
Sep 12, 2024

Intellia Therapeutics to Present Data from the Phase 2 - GlobeNewswire

Sep 12, 2024
pulisher
Sep 12, 2024

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting - Yahoo Finance

Sep 12, 2024
pulisher
Sep 11, 2024

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) - GlobeNewswire

Sep 11, 2024
pulisher
Sep 10, 2024

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 - Newsfile

Sep 10, 2024
pulisher
Sep 09, 2024

Protara Therapeutics Announces Completion of First Cohort - GlobeNewswire

Sep 09, 2024
pulisher
Sep 03, 2024

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial - GlobeNewswire

Sep 03, 2024
pulisher
Sep 03, 2024

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts - Yahoo Finance

Sep 03, 2024
pulisher
Sep 03, 2024

Dyne Therapeutics Announces New Clinical Data from Phase - GlobeNewswire

Sep 03, 2024
pulisher
Aug 27, 2024

Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients (SLNO) - Seeking Alpha

Aug 27, 2024
pulisher
Aug 26, 2024

Innovo Therapeutics Inc. Announces Phase 2 Clinical Results Demonstrating the Innovative Efficacy of INV-001 for the Treatment of Post-thyroidectomy Scars - Winchester Herald Chronicle

Aug 26, 2024
pulisher
Aug 23, 2024

Director J Singleton Sells 5,700 Shares of Viking Therapeutics Inc (VKTX) - Yahoo Finance

Aug 23, 2024
pulisher
Aug 22, 2024

Cognition Therapeutics Publishes EEG Findings from Phase 2 - GlobeNewswire

Aug 22, 2024
pulisher
Aug 22, 2024

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease - Yahoo Finance

Aug 22, 2024
pulisher
Aug 21, 2024

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - Yahoo Finance

Aug 21, 2024
pulisher
Aug 20, 2024

iTeos Therapeutics Announces Late-Breaking Oral - GlobeNewswire

Aug 20, 2024
pulisher
Aug 20, 2024

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 - Yahoo Finance

Aug 20, 2024
pulisher
Aug 19, 2024

Scorpion Therapeutics to Present STX-478 Initial Phase 1/2 Data at ESMO Congress 2024 - Business Wire

Aug 19, 2024

An 2 Therapeutics Inc Azioni (ANTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):